Table 1.

Targeting various diseases by curcumin supplementation. A large number of clinical trials have been conducted to evaluate the beneficial effects of Curcumin supplementation and have been summarized by Gupta et al.⁸⁶ Listed below are some of the recent trials for modulation of targeted diseases.

Target Disease	Dose/Formulation of Curcumin	Clinical Findings	Ref. #
Obesity	1 g/day for 4 weeks	Reduced IL-1b, IL-4, VGEF	8
	500 mg/day for 12 weeks	Reduced LDL and lipid peroxidation	9
Metabolic syndrome	2 g/day for 12 weeks	Reduced LDL, TG	10
	45–180 mg/day	No effect	11
Diabetes	Meriva® (200 mg/day) for 4 weeks	Improved blood flow in skin and retina	12,13
	200 mg/day for 9 months to pre-diabetics	Prevention of diabetes development	14
	500 mg/day for 15–30 days	Reduction in oxidative status	15
Fatty liver disease	Meriva® (1 g/day) for 8 weeks	Reduced BMI, waist circumference, and improved liver function	16
	70 mg/day for 8 weeks	Reduced liver fat, improved liver function	17
Cancer	6 g/day with docetaxel for 6 cycles	Reduced PSA in this resistant population	18
	2 g/day with radiotherapy	Reduces radiation dermatitis (Breast cancer patients)	19
	Dose escalation up to 8 g/day with docetaxel	Increased tolerance to docetaxel and reduced cancer (metastatic breast cancer)	20
	Theracurmin (200 mg – 8 g) with Gemcitabine	Plasma levels in ng/ml range, reduced inflammation and some protection but curcumin well tolerated at these high doses (Abdominal fullness, diarrhea)	21
Depression	2 g/day along with anti-depressives	Reduced cytokines but increased brain derived-neurotropic factor; improved depression scores	22
	500 mg/day Curcumin with Fluoxetine	Faster recovery	23
Arthritis	Theracurmin (150 mg/day) for 8 weeks	Reduced knee pain score	24
	Fexofytol® (42 mg/day) for 3 months	Reduced pain and plasma cartilage specific marker	25
	Meriva® (200 mg/day) for 3–8 months	Reduced arthritis score and plasma CRP; reduced use of painkillers	26,27
	Curcumin (500 mg/day) with diclofenac	Higher improvement in pain scores	28